Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...
Nasdaq10d
Opus Genetics, Inc. Announces Acceptance of Three Abstracts for Presentation at ARVO 2025 Meeting
The abstracts include 12-month data from the Phase 1/2 trial of OPGx-LCA5, information on pre-clinical studies of OPGx-MERTK and OPGx-RDH12, and a subset analysis from the LYNX-1 Phase 3 trial of ...